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Abstract
Autoimmune diseases have a higher prevalence of cardiovascular events compared to the
general population. The objective of this study was to investigate the genetic basis of cardio-
vascular disease (CVD) risk in autoimmunity. We analyzed genome-wide genotyping data
from 6,485 patients from six autoimmune diseases that are associated with a high socio-
economic impact. First, for each disease, we tested the association of established CVD risk
loci. Second, we analyzed the association of autoimmune disease susceptibility loci with
CVD. Finally, to identify genetic patterns associated with CVD risk, we applied the cross-
phenotype meta-analysis approach (CPMA) on the genome-wide data. A total of 17 estab-
lished CVD risk loci were significantly associated with CVD in the autoimmune patient
cohorts. From these, four loci were found to have significantly different genetic effects
across autoimmune diseases. Six autoimmune susceptibility loci were also found to be
associated with CVD risk. Genome-wide CPMA analysis identified 10 genetic clusters
strongly associated with CVD risk across all autoimmune diseases. Two of these clusters
are highly enriched in pathways previously associated with autoimmune disease etiology
(TNFα and IFNγ cytokine pathways). The results of this study support the presence of spe-
cific genetic variation associated with the increase of CVD risk observed in autoimmunity.
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Introduction
Autoimmune diseases are a group of highly disabling chronic disorders characterized by the
activation of multiple immune and inflammatory pathways against the self [1]. Overall, the
estimated prevalence of autoimmunity is 5–7% in the general population [2]. Among these,
the six autoimmune diseases that are associated with a high socio-economic impact are psoria-
sis (PS), rheumatoid arthritis (RA), psoriatic arthritis (PA), systemic lupus erythematosus
(SLE) and inflammatory bowel diseases (IBDs), including Crohn’s disease (CD) and ulcerative
colitis (UC). Importantly, patients with autoimmune diseases have shown to have a higher risk
to develop cardiovascular diseases (CVD) compared to the general population [3]. Under-
standing the genetic and biological mechanisms underlying CVD risk in autoimmunity could
therefore be fundamental to develop more efficient preventive and therapeutic strategies.
Autoimmune diseases are genetically complex diseases [4]. In the last years, genome-wide
association studies (GWAS) have proven highly successful for identifying a large number of
disease susceptibility loci [5]. In IBDs, for example, there are now more than 160 risk loci
known to be associated to these autoimmune diseases of the gut [6]. Importantly, GWAS have
enabled the identification of a shared genetic risk across autoimmune diseases [7]. However,
little is known yet about the genetic variation that contributes to clinically relevant phenotypes
within each autoimmune disease.
From a clinical perspective, one of the most important phenotypes in autoimmune diseases
is the development of CVD. The marked reduction of the life expectancy observed in autoim-
mune patients has been clearly associated with an increased risk of CVD [8]. To date, multiple
epidemiological and clinical factors have been associated with CVD risk both in autoimmune
diseases and in the general population. These include age, dyslipidemia, arterial hypertension
and obesity. However, there is increasing evidence that the elevated risk of CVD observed in
autoimmune diseases is only partially explained by these classical risk factors [9]. In turn,
GWAS in case-control cohorts from the general population have demonstrated the existence
of a genetic risk background for CVD [10]. To date, more than 25 GWAS for CVD have been
performed, resulting in the identification of more than 100 genetic risk variants [11–13]. So
far, however, little is known on the impact of these established genetic variants in the risk of a
cardiovascular event in autoimmune diseases.
A large number of the genetic variation associated with the susceptibility to autoimmune
diseases involves genes associated with the innate and adaptive immune responses [14]. In
particular, these include variation at pathways from pro-inflammatory cytokines like Tumor
Necrosis Factor alpha (TNFα) and interferon gamma (IFNγ) [15]. There is increasing evidence
that inflammation and immune response activity are also important factors to CVD risk in
the general population, both at the genetic and at the functional level [16, 17]. Consequently,
genetic variants associated with autoimmune disease susceptibility could also contribute to the
increase in CVD risk observed in this group of diseases. To date, however, no comprehensive
study of the association between autoimmune susceptibility variants with CVD risk has been
performed.
GWAS have revealed that many autoimmune risk loci are associated with multiple autoim-
mune diseases but not necessarily in the same direction (i.e. a risk allele for a particular auto-
immune disease can act as a protective allele for other autoimmune diseases) [7]. These
complex cross-phenotype associations underscore the importance of pleiotropy in the genetic
epidemiology of autoimmunity. Pleiotropy occurs when a gene or genetic variant affects more
than one phenotypic trait. Accordingly, the use of GWAS methods embracing this prevalent
property should increase the power to identify relevant genetic variation in autoimmune
diseases.
Genetics of CVD risk in autoimmune diseases
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In the present study, we have used a large cohort of patients to investigate the genetics of
CVD in six of the most clinically relevant autoimmune diseases. For this objective we have
tested, for the first time, the association between established CVD risk loci and the develop-
ment of CVD in autoimmunity. Conversely, we have also analyzed the association between
autoimmune-disease loci and CVD risk. Finally, in order to identify new genetic variation
associated with CVD risk across autoimmune diseases, we have performed a genome-wide
cross-phenotype analysis. Together, the results of this study provide novel insights into the
genetic basis of CVD in autoimmune diseases.
Materials and methods
Study population
A total of 6,485 patients were recruited by the Immune-Mediated Inflammatory Disease Con-
sortium (IMIDC) between June 2007 and December 2010 [18]. The IMIDC is a Spanish net-
work of clinical researchers aimed at characterizing the genetic basis of autoimmune diseases.
All patients were collected from the outpatient’s clinics of more than 80 departments of rheu-
matology, dermatology and gastroenterology from 51 Spanish University Hospitals belonging
to the IMIDC. The cohort of patients used for the present study included: (i) 1,281 RA patients
that fulfilled the American College of Rheumatology (ACR) diagnostic criteria; (ii) 1,123 PS
patients that were diagnosed based on the dermatologist clinical criteria; (iii) 989 PA patients
that fulfilled the Classification Criteria for Psoriatic Arthritis (CASPAR); (iv) 907 SLE patients
that fulfilled four or more of the 1982 revised ACR criteria for SLE classification; and (v) 2,185
IBD patients, including 1,358 and 827 patients that were diagnosed using the Lennard-Jones
criteria as having CD and UC, respectively (S1 File). All patients were of Western European
descent and with all four grandparents born in Spain. The main features of the different
patient cohorts are summarized in S1 Table.
All the procedures were followed in compliance with the principles of the Declaration of
Helsinki and informed written consent was obtained from all participants. The study and the
consent procedure were reviewed and approved by the Ethics Committee of Clinical Research
from Vall d’Hebron Hospital Research Institute.
Cardiovascular disease phenotype
CVD is a heterogeneous phenotype that includes diverse clinical endpoints. In the present
study, CVD patients were defined as having 1 out of the 3 most frequent cardiovascular phe-
notypes: coronary heart disease (CHD), cerebrovascular accident (CVA) and peripheral arte-
rial disease (PAD). The medical history of CVD was obtained after a detailed and exhaustive
interrogation using standardized medical questionnaires provided. These medical question-
naires were filled by medical specialists from all Spanish Hospitals involved in the IMID Con-
sortium according to the CVD definitions described below.
The CHD phenotype was defined as history of angina, acute myocardial infarction or ische-
mic heart diseases. The history of angina was assessed as evidence of acute-event symptoms
including jaw, arm or chest pain as well as other clinically-related cardiac ischemia symptoms.
The history of acute myocardial infarction was examined as the evidence of myocardial necro-
sis that is consistent with a myocardial ischemia. This was detected by a significant increase/
decrease of the levels of the main cardiac biomarkers, together with a characteristic change in
the electrocardiogram of the patient. The history of ischemic heart disease was confirmed if
the patient fulfilled any of the following conditions: (i)1 major epicardial coronary arteries
having more than 70% of obstruction; (ii) history of acute myocardial infarction associated
with wall motion abnormality; or (iii) diagnosis of coronary artery disease.
Genetics of CVD risk in autoimmune diseases
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The CVA phenotype was used to characterize those autoimmune disease patients that had a
transient ischemic attack or an ischemic/hemorrhagic stroke. The appearance of a transient
ischemic attack was defined as a brief neurological dysfunction of the brain (i.e. lasting < 24
hours) caused by a cerebral ischemia without acute infarction. The history of an ischemic/
hemorrhagic stroke was defined as an acute episode of focal, cerebral, spinal, or retinal dys-
function caused by infarction/hemorrhage of the central nervous system tissue.
The PAD phenotype was defined as the narrowing of the peripheral arteries that is caused
by the presence of atherosclerotic plaques. Claudication symptoms are one of the most impor-
tant PAD subphenotypes that were used to characterize the CVD phenotype of autoimmune
disease patients. Clinical data from surgical and non-surgical interventions like coronary
revascularization or percutaneous stenting were not collected in the IMID medical question-
naires and, consequently, these clinical subphenotypes were not evaluated in the present study.
Importantly, to identify genetic variation specifically associated with CVD risk in autoim-
munity, all patients that had a cardiovascular event before the date of autoimmune disease
diagnosis were excluded from the study (N = 127 patients).
GWAS genotyping and quality control
Genome-wide genotyping data from RA, PS, PA, CD and UC patients were obtained from the
five cohorts of autoimmune patients that we previously genotyped [18–22]. For the SLE
cohort, whole blood samples (5 mL) were collected from 907 SLE patients. From each sample,
genomic DNA was isolated using the Chemagic Magnetic Separation Module I (PerkinElmer,
Waltham, MA). Whole genome genotyping in the SLE patient cohort was performed using the
same array platform (Illumina Quad610 BeadChip). Genotype calling was performed using
the GenomeStudio software (v2011.1, Illumina, San Diego, California, USA).
From the 598,258 SNPs genotyped for each patient, we selected all 582,539 autosomal SNPs
for the quality control (QC) analysis. In this analysis, we excluded those SNPs that had a minor
allele frequency (MAF) < 0.05 and> 5% of missing data (5.6% SNPs). In order to identify
markers deviating from Hardy-Weinberg equilibrium, we used an additional cohort of 1,558
healthy controls from the same population and genotyped with the same array [19]. A total of
1,649 SNPs that deviated significantly from Weinberg equilibrium in this cohort were subse-
quently removed (0.03% SNPs, P<1e-4). To evaluate the presence of potential population
stratification in the autoimmune patient cohorts, we used the principal component analysis
(PCA) implemented in EIGENSOFT (v4.2) software (v4.2) [23]. Using the first 10 PCs of vari-
ation over 10 iterations we identified and discarded 201 patients showing an outlier genetic
background (NRA = 32, NPS = 50, NPA = 20, NSLE = 18, NCD = 64, NUC = 17, S1 Fig). After the
quality control, a final data set of 506,919 SNPs and 5,317 patients was available for association
analysis.
Selection of candidate markers for CVD risk
Genetic variants associated with CVD risk in the general population. Genetic variants
previously associated with CVD risk phenotypes (including IHD, CVA or PAD) in the general
population (S2 Table) were obtained through a comprehensive electronic data search using
PubMed (www.ncbi.nlm.nih.gov/pubmed, 4th February 2016). Only established CVD risk loci
(i.e. genetic variants that were significant at the genome-wide scale, P<5E-8), were selected for
the present study. A total of 115 genome-wide significant variants were identified and subse-
quently tested for association with CVD in each for the six autoimmune diseases.
Genetic variants associated with autoimmune disease susceptibility. Genetic variants
associated with disease susceptibility were obtained from recently published GWASs [6, 24–
Genetics of CVD risk in autoimmune diseases
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27]. A total of 341 genome-wide significant autoimmune disease variants were identified and
tested for association with CVD risk (S3 Table).
Genotype imputation
The CVD and autoimmune risk SNPs that were not directly genotyped in the GWAS array (N
= 85 CVD risk SNPs and N = 244 autoimmune risk SNPs) were imputed using the data from
the six patient cohorts. After pre-phasing the haplotypes of each genomic region using SHA-
PEIT V2-644 software (Oxford, UK), imputation was carried out using IMPUTE V2 software
(Oxford, UK) [28]. Genotype imputation was performed using the dense genotyping data
from the Caucasian European cohort (N = 379 samples) generated by the 1000 Genomes Proj-
ect (phase 1, version 3) [29]. Only those SNPs with high quality scores (defined as having an
info quality metric > 0.8) were selected for downstream analysis. A total of 73 CVD risk SNPs
and 218 autoimmune risk SNPs passed imputation quality control. After the imputation step,
a final set of 103 CVD risk SNPs and 315 autoimmune risk SNPs was available for the candi-
date association analysis.
Statistical association analysis
Using the final data set of QC-filtered SNPs, the statistical association analysis between each
variant and CVD risk was performed using the logistic regression model based on the expected
genotype counts and implemented in SNPTEST v2 software (Oxford, UK) [30]. In this
method, the allele dosage is defined as follows:
Allele Dosagei ¼
X2
g¼0
PrðG ¼ gÞ  g
Where g represents each genotype of a particular genetic variant i, and Pr(G = i) is the mar-
ginal posterior probability obtained by imputation. The allele dosage therefore can take values
between 0 and 2.
Traditional CVD risk factors are known to contribute to CVD risk both in the general pop-
ulation and in patients with autoimmune diseases [3]. Therefore, if inadequately controlled,
these clinical and epidemiological risk factors could confound the results from CVD genetic
association studies. In order to avoid the effect of these confounding factors, we included the
established CVD risk factors as covariates in the statistical association analysis. Accordingly,
age, sex, dyslipidemia, arterial hypertension, diabetes mellitus type 2, body mass index, physi-
cal inactivity and smoking were included as covariates in the logistic regression model (S1
File). Also, in order to control for genetic ancestry the 2 first PCs of variation were included as
covariates in the logistic regression model. The summary statistics of the traditional CVD risk
factors for each autoimmune disease are shown in S1 Table.
In order to compare the genetic effect of the associated SNPs across autoimmune diseases,
we used the Breslow-Day test for homogeneity of the odds ratio. This method was applied to
compare the genetic effect across all autoimmune diseases and also across the two most closely
related autoimmune diseases at the clinical level: (i) PS and PA; (ii) CD and UC; and (iii) RA
and SLE.
Genome-wide cross-phenotype analysis of CVD risk
In order to identify genetic patterns associated with CVD risk in autoimmune diseases, we per-
formed a genome-wide cross-phenotype meta-analysis (CPMA) as described previously [7].
Briefly, CPMA is a novel approach that allows the identification of genetic variants associated
Genetics of CVD risk in autoimmune diseases
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with multiple phenotypes by integrating statistics from GWAS. First, genome-wide signifi-
cance P-values for CVD risk were calculated for each autoimmune disease using a total of
507,051 SNPs. The SNPs that were found to be nominally associated with CVD risk were then
selected (P<0.05, N = 10,163 SNPs, here) and used to calculate the CPMA statistic. The CPMA
statistic efficiently integrates the evidence from multiple phenotypes and tests for the presence
of pleiotropic associations. After selecting the SNPs with significant evidence of pleiotropy
(PCPMA<0.01), we filtered those variants that were in moderate to high linkage disequilibrium
(r2>0.2) in order to avoid the inclusion of redundant signals from neighboring markers.
After identifying the independent SNPs showing higher evidence of pleiotropy, we next
analyzed the presence of genetic patterns associated with CVD risk in autoimmune diseases.
Following the previously described approach, we computed the SNP-SNP distances and we
classified them into four categories of statistical association (i.e. 1>P>0.05, 0.05>P>0.02,
0.02>P>0.005, P<0.005) [7]. The categorical matrix defined by these four categories (i.e. each
row represents a SNP associated with CVD and each column a particular autoimmune disease)
was used to compute the Euclidean distance between each SNP pair using the Gower’s method
for discrete data. The resulting matrix of SNP-SNP Euclidean distances was finally used to per-
form the hierarchical clustering analysis using Ward’s method. All the steps from the cross-
phenotype analysis were performed using the R statistical software.
For each genetic risk pattern, we computed the statistical significance of the association with
CVD risk by combining the association statistics using Fisher’s method. According to the number
of genetic patterns and autoimmune diseases tested for association with CVD risk, the statistical
significance was then corrected for multiple testing using the Bonferroni method [31]. In order to
functionally characterize each genetic pattern, we performed a functional enrichment analysis.
For this objective, we used the "Hallmark Gene Sets" database (Molecular Signatures Database,
Boston, www.broadinstitute.org/gsea/msigdb), a collection of curated sets of genes that show
strong coordinated gene expression and represent specific well-defined biological processes. The
statistical enrichment analysis for each functional gene set was calculated using the hypergeomet-
ric test. The False Discovery Rate (FDR) method was used to account for multiple testing [32].
Results
CVD characterization in autoimmune disease cohorts
A total of 140 autoimmune patients with CVD and 5,317 event-free autoimmune patients
were identified in the autoimmune disease cohorts of the present study. The epidemiological
and clinical characteristics of the present cohort are shown in S1 Table.
Identification of established CVD risk variants associated also with CVD
in autoimmune diseases
We successfully replicated the association between 17 genetic variants and CVD risk in the dif-
ferent autoimmune diseases (P<0.05, same risk allele, Table 1). Of relevance, none of the asso-
ciated SNPs overlapped between the different autoimmune diseases. The most significant
association was observed between HHIPL1 gene (intronic SNP rs2895811) and CVD risk in
CD (P = 5.62E-4).
Identification of heterogeneous effects on CVD risk across autoimmune
diseases
From the 17 genetic variants that were significantly associated with CVD risk, we found that 4
SNPs showed significant heterogeneity of genetic effects across the six autoimmune diseases
Genetics of CVD risk in autoimmune diseases
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(PBreslow-Day<0.05, Fig 1). Three of these variants displaying significant heterogeneous associa-
tion with CVD risk were associated with IBDs: SNP rs17465637 (MIA3 gene; P = 0.03; OR =
6.76; 95% CI, 1.21–37.96) and SNP rs2895811 (HHIPL1 gene; P = 0.001; OR = 8.51; 95% CI,
1.80–80.02) were associated with CD, and SNP rs6789378 (OTOL1-TOMM22P6 locus; P =
0.004; OR = 7.52; 95% CI, 2.11–40.78) with UC. Comparing the genetic effect on CVD risk
between the most clinically similar autoimmune diseases, we detected significantly different
effects in 5 out of the 17 CVD risk SNPs (PBreslow-Day<0.05, Table 1).
Identification of autoimmune disease risk variants associated with CVD
risk
A total of 6 SNPs associated with autoimmune disease risk were also found to be significantly
associated with CVD risk (P<0.05, Table 2). Four of these variants were IBD risk SNPs and
two were markers associated with RA susceptibility.
Genetic patterns associated with CVD risk in autoimmune diseases
A total of 765 SNPs were found to have a significant multi-phenotype association (PCPMA<0.01,
PBinomial<5.74E-28). After removing the markers in linkage disequilibrium (r2>0.2), a final set
of 406 independent pleiotropic SNPs was used for downstream analysis (S4 Table). The global
sharing of genetic associations with CVD risk across the six autoimmune diseases is represented
in S2 Fig.
Table 1. Established CVD risk variants associated with CVD risk in the six autoimmune diseases.
Gene SNP Chr Position IQM RA AID P OR (95% CI) AIDBR PBD
BSND,PCSK9 rs11206510 1 55030366 DG T UC 0.041 6.56 (1.07–40.09) CD 0.303
MIA3 rs17465637 1 222650187 1.00 C CD 0.029 6.76 (1.20–37.96) UC 0.058
SORT1,CELSR2,PSRC1 rs602633 1 109278889 0.96 T PA 0.027 2.57 (1.11–5.90) PS 0.108
OTOL1,TOMM22P6* rs6789378 3 162449608 1.00 G UC 0.004 5.54 (1.72–17.8) CD 0.014
OTOL1,TOMM22P6 rs11924705 3 162443828 1.00 T PA 0.009 2.90 (1.30–6.50) PS 0.085
STK32B rs7673097 4 5366497 0.99 G UC 0.039 1.79 (1.01–12.50) CD 0.935
MTND1P22,GUCY1A3 rs1842896 4 155590307 DG T SLE 0.046 1.96 (1.01–3.80) RA 0.210
LPA rs10755578 6 160548706 0.99 C UC 0.027 4.16 (1.17–14.74) CD 0.632
ZPR1 rs964184 11 116778201 DG G CD 0.037 1.10 (1.01–4.98) UC 0.917
PTCSC3 rs1952706 14 36205321 0.98 C SLE 0.036 2.11 (1.05–4.23) RA 0.053
HHIPL1* rs2895811 14 99667605 DG C CD 5.62E-4 34.11 (4.58–254.06) UC 0.025
ADAMTS7* rs3825807 15 78796769 1.00 A SLE 0.049 1.93 (1.03–3.74) RA 0.020
ZFHX3 rs879324 16 73034779 0.98 A UC 0.016 4.75 (1.34–16.78) CD 0.358
UBE2Z* rs46522 17 48911235 1.00 T PA 0.012 2.67 (1.24–5.77) PS 0.027
SMARCA4* rs1122608 19 11052925 0.98 T RA 0.039 1.69 (1.03–2.78) SLE 0.013
AP3D1,SF3A2,DOT1L rs3803915 19 2160530 DG C PA 0.029 3.09 (1.21–126.53) PS 0.286
APOE rs2075650 19 44892362 DG G PA 0.024 3.50 (1.17–10.41) PS 0.122
Gene: closest mapping gene/s to the associated SNP; SNP: Single Nucleotide Polymorphism; Chr: chromosome; IQM: Information quality metric obtained
in the imputation step for the indicated genetic variant (DG indicates that a particular genetic was directly genotyped); RA: allele associated with CVD risk in
the original publication; AID: autoimmune disease where the CVD risk variant was replicated; P: P-value of association of variant with CVD risk in the
autoimmune diseases; OR (95% CI): odds ratio and 95% confidence interval of the association between the SNP and CVD risk; AIDBR: most closely related
autoimmune disease; PBD: significance of Breslow-Day test for heterogeneity of effect of the CVD risk SNP between the two most closely related
autoimmune diseases.
* Genes showing a significantly different genetic effect on CVD risk between the two most closely related autoimmune diseases (PBD<0.05).
https://doi.org/10.1371/journal.pone.0185889.t001
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Using the clustering approach on the 406 pleiotropic variants, we identified 10 different
genetic clusters (GC) associated with CVD risk in autoimmune diseases (Fig 2A and S5 Table).
For each autoimmune disease, the statistical association between each GC and CVD risk is
shown in Fig 2B. From the 10 GCs identified, we found that 3 GCs were significantly enriched
Fig 1. Genetic variants showing heterogeneous genetic effects on CVD risk across autoimmune diseases. For each associated SNP (A:
rs17465637. B: rs11924705. C: rs2895811. D: rs6789378) the Odds Ratio (OR, black dots) and 95% confidence intervals (horizontal lines) are shown for
each of the 6 autoimmune diseases and the combined autoimmune cohort (AID). The SNPs showing a significant association with CVD risk in an
autoimmune disease are highlighted in red. For each of the three genotypes of each SNP (risk allele homozygous, heterozygous, non-risk allele
homozygous), the incidence of CVD is described in the accompanying table.
https://doi.org/10.1371/journal.pone.0185889.g001
Table 2. Established autoimmune susceptibility variants also associated with CVD risk.
Autoimmune disease SNP Chr Position IQM Gene RA P OR (95% CI)
Rheumatoid arthritis rs6732565 2 110850255 1.00 ACOXL A 0.021 1.74 (1.09–2.79)
Rheumatoid arthritis rs6715284 2 201289674 0.99 CFLAR-CASP8 G 0.028 2.35 (1.09–5.04)
Crohn’s disease rs7702331 5 73255307 DG LOC105379031 A 0.029 5.52 (1.19-25-71)
Crohn’s disease rs212388 6 159069404 DG TAGAP C 0.044 5.51 (1.04–29.11)
Crohn’s disease rs3897478 1 119908567 1.00 ADAM30 T 0.038 1.83 (1.01–78.24)
Ulcerative colitis rs4728142 7 128933913 DG IRF5 A 0.011 4.68 (1.43–15.30)
SNP: Single Nucleotide Polymorphism; Chr: chromosome; IQM: Information quality metric obtained in the imputation step for the indicated genetic variant
(DG indicates that a particular genetic was directly genotyped); Gene: closest mapping gene/s to susceptibility variant; RA: allele associated with
autoimmune disease risk; P: significance of association between the indicated genetic variant and CVD risk; OR (95%CI): Odds ratio and 95% confidence
interval for the observed association.
https://doi.org/10.1371/journal.pone.0185889.t002
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in 7 sets of functionally-related genes (Table 3 and S6 Table). Importantly, after multiple test-
ing correction, GC4 and GC7 were found to be significantly enriched in genes that are
involved in immune-related pathways strongly associated with the autoimmunity etiopatho-
genesis like the TNFα (PFDR = 0.02) and INFγ cytokine pathways (PFDR = 0.02), respectively.
Discussion
CVD represents one of the most clinically relevant phenotypes in autoimmune diseases. In
this work, we have used a large multicenter cohort of six autoimmune diseases to characterize
the genetic risk for CVD in this group of diseases. First, we have replicated the association of
established CVD risk loci with CVD in autoimmune diseases. Second, we have found that mul-
tiple autoimmune susceptibility loci are also associated with CVD risk. Finally, using a cross-
phenotype genome-wide analysis we have identified genetic patterns significantly associated
with CVD risk in autoimmune diseases. Taken together, these findings support the existence
of a differential genetic component for CVD risk in autoimmunity.
We have successfully validated the association of 17 established CVD risk SNPs in autoim-
mune diseases. This result confirms that genetic variation associated with the development of
cardiovascular events in the general population can also be associated with CVD risk in this
group of chronic inflammatory diseases. Several of these associated genes have relevant func-
tional implications that could link both disease etiopathogenesis. For example, ADAMTS7
(rs3825807) encodes a metalloproteinase that has been associated with arthritis and also with
the thickening of the neointima occurring in cardiovascular events [33, 34]. The association
between CVD risk and SMARCA4 (rs1122608) in RA patients is also consistent with the dis-
ease pathogenesis. RA is characterized by the predominant infiltration of CD4+ T lymphocytes
in the synovial joints. SMARCA4 (also known as BRG1) has been shown to be essential for the
differentiation of Th1 CD4+ T cells [35], which is the predominant T cell subset in RA synovial
joints. Conversely, variation at SMARCA4 gene has been recently associated to low-density
lipoprotein cholesterol and apolipoprotein B levels [36], thereby providing a direct etiological
contribution to CVD risk.
One of the most important findings of the present study is the identification of differential
effects in established CVD risk genes across autoimmune diseases. This result suggests that the
proinflammatory state that characterizes each autoimmune disease modulates specifically the
CVD risk conferred by the known CVD genetic risk factors. For example, the genetic risk vari-
ant rs2895811 at HHIPL1 gene showed a significantly stronger association with CVD risk in
CD than in the other five autoimmune diseases. The protein encoded by this gene participates
in the Hedgehog (HH) signaling pathway, a biological process known to be involved in the
pathogenesis of IBDs [37]. Very recently, this signaling pathway has been shown to play also a
cardio-protective role in cardiomyocytes [38]. This result therefore suggests that the pathologic
role of the HH signaling pathway in CVD is enhanced by the specific autoimmune processes
activated in CD and, therefore, that CD patients carrying the risk allele for the HHIPL locus
have a higher probability to develop a cardiovascular event than patients with the non-risk
allele. To our knowledge, it is the first time that genetic risk factors for CVD have been shown
to be modulated by the presence of an autoimmune disease.
The use of GWAS to identify new genetic risk loci for autoimmune diseases has greatly
improved our understanding of the genetic basis of autoimmunity risk [39]. Together with the
characterization of the missing heritability, the challenge ahead is to investigate whether these
autoimmune disease risk loci are also associated to the most clinically relevant disease pheno-
types. CVD is clearly one of the most relevant phenotypes since it has a direct impact in the
patient’s life expectancy. In the present study we have analyzed the association between known
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Fig 2. Identification of the genetic clusters associated with CVD risk across autoimmune diseases. A: Hierarchical clustering dendrogram showing
the similarity between SNPs with significant evidence of pleiotropy with CVD risk. B: Statistical significance of the association between each genetic cluster
and CVD risk for the six autoimmune diseases. Significant associations after multiple test correction are highlighted in white boxes. Abbreviations: GC:
genetic cluster.
https://doi.org/10.1371/journal.pone.0185889.g002
Genetics of CVD risk in autoimmune diseases
PLOS ONE | https://doi.org/10.1371/journal.pone.0185889 October 5, 2017 10 / 17
susceptibility variants for autoimmune diseases and CVD risk. For most of these loci it is the
first time that this association has been tested. Despite immune activation is now considered a
necessary biological process for CVD development [40], to date, very few established CVD risk
genes are known to be associated with immunity. Our findings support the existence of a
genetic risk component for CVD that is functionally associated with the immune response.
In the association analysis between candidate loci and CVD risk, we were able to identify a
significant association for 6 out of 315 autoimmune-associated SNPs and 17 out of 103 CVD-
associated SNPs. Although GWAS are a very powerful approach to identify new disease risk
genes, this methodology is not always able to identify the exact causal variant [41]. The genetic
variation analyzed in the present study (i.e. reference SNPs for both CVD and autoimmunity
risk) could be in linkage disequilibrium with the exact causal SNP rather than being the precise
causal variant itself. Also, different genetic variation at the same gene has been associated with
multiple autoimmune diseases [42]. This suggests that causative SNPs for CVD could differ
between diseases, which is consistent with the differences observed across the six autoimmune
diseases analyzed. Future studies using independent cohorts of CVD-characterized autoim-
mune disease patients will provide deeper insights into the disease-specific genetic basis for
CVD risk in autoimmunity.
In the present study we have also identified the existence of genetic patterns associated with
CVD risk across autoimmune diseases. Based on the existence of pleiotropic effects among
genetic variation associated with autoimmune disease risk, we have been able to combine the
results across six autoimmune diseases and identify 10 genetic patterns associated with
CVD risk. Of relevance, two of these genetic patterns are significantly enriched in genes from
immune response pathways that are crucial for this group of autoimmune diseases: TNFα
and IFNγ cytokine pathways. The GC enriched in TNFα pathway genes was found to be very
strongly associated with CVD risk in RA and SLE (P = 1.8E-38 and P = 4.36E-42, respectively).
TNFα is one of the main mediators of multiple cardiovascular pathological mechanisms
underlying CVD [15]. In addition, TNFα is one of the most abundant cytokines produced by
the inflamed synovium in RA. Blocking TNFα systemically has proven to be a highly effica-
cious approach to treat RA, and is currently the predominant biologic therapy after failure of
conventional disease-modifying anti-rheumatic drugs. Consequently, genetic variation influ-
encing this shared pathway could contribute to increase the risk of a cardiovascular event in
RA patients. Evidence from national registers suggesting that patients treated with anti-TNF
agents have a lower probability to develop CVD supports this possibility [43]. In order to iden-
tify the therapeutic potential of these results, further studies evaluating the role of TNFα in the
Table 3. Functional characterization of the genetic clusters associated with CVD risk across autoimmune diseases.
GC Gene Set Description Gene# PHYPER PFDR
GC 4 Apical surface Genes encoding proteins over-represented on the apical surface of epithelial cells. 44 7,17E-4 0.019
GC 4 TNFα signaling via NFKB Genes regulated by NFKB in response to TNF. 200 7,66E-4 0.019
GC 6 Estrogen response early Genes defining early response to estrogen. 200 5,21E-4 0.013
GC 6 Estrogen response late Genes defining late response to estrogen. 200 5,21E-4 0.013
GC 7 Adipogenesis Genes up-regulated during adipocyte differentiation. 200 1,01E-3 0.017
GC 7 Complement Genes encoding components of the complement system. 200 1,01E-3 0.017
GC 7 Interferon Gamma response Genes up-regulated in response to IFNγ. 200 1,01E-3 0.017
GC: genetic cluster; Gene Set: Hallmark gene set associated with CVD risk; Gene#: number of genes in the indicated gene set; PHYPER: significance of
association between the indicated GC and biological process using the hypergeometric test; PFDR: significance of the functional association after correcting
for multiple testing using the False Discovery Rate method.
https://doi.org/10.1371/journal.pone.0185889.t003
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development of CVD in RA and SLE patients as well as the role of IFNγ in PA and RA patients
are needed.
The functional enrichment analysis of the genetic clusters associated with CVD risk in
autoimmune diseases also showed a genetic cluster (GC6) significantly enriched in genes
that participate in the estrogen response. For decades, it has been known that there is a higher
prevalence of CVD in males compared to females. This observation has contributed to the
hypothesis that sex-related hormones like estrogens, which are also potent stimulators of
autoimmunity, contribute to the risk of developing CVD [44, 45]. The finding that estrogen
response genes (GC6) are associated with CVD in PS and RA suggests that, within these two
autoimmune diseases, the role of sex hormones in increasing CVD risk is partially mediated
by genetic variation at genes participating in the estrogen response.
This study represents the first comprehensive analysis of genetic variation associated with
CVD risk in autoimmune diseases. Our findings provide new insights into the molecular mech-
anisms that contribute to increase the risk of a cardiovascular event in autoimmune diseases.
Nevertheless, this study has limitations. Despite that the sample size used in each of the six auto-
immune diseases is large, the number of patients with CVD events is relatively low. The main
reason is the low prevalence of this severe phenotype within each disease cohort but also the
exclusion of patients that had a CVD event before the autoimmune disease initiation. This
former selection criteria, although reduced the total number of CVD patients available for anal-
ysis, was essential to identify the genetic variation that is relevant for CVD in autoimmunity.
Another limiting factor in this study is the heterogeneity in the CVD phenotype. Similar to pre-
vious studies, we included patients with different forms of CVD, and this could have prevented
the identification of additional genetic associations. It is likely that stratified analyses for each of
the different CVD subphenotypes will help to reveal new risk variation, although this would
require much larger patient cohorts than the ones used in the present study. Future studies inte-
grating data from different multicenter cohorts like the present one will be necessary.
In the present study we have performed a comprehensive analysis of genetic variation associ-
ated with CVD risk in autoimmune diseases. Using large cohorts of six autoimmune diseases
that are associated with a high socio-economic impact, we have replicated the association of
established CVD risk loci. Importantly, we have found that several of these loci are differentially
associated across autoimmune diseases. This result supports the hypothesis that the disease-spe-
cific inflammatory component contributes differentially to increase CVD risk in autoimmunity.
In addition, we have identified genetic variation previously associated with autoimmune dis-
eases susceptibility that is also associated with CVD risk. This result could contribute to explain
the increased prevalence of CVD observed in autoimmune diseases. Replication in additional
independent cohorts will be needed to confirm this finding. Finally, we have identified the
major genetic patterns associated with CVD risk in autoimmune diseases. These results suggest
novel biological mechanisms underlying the development of CVD in autoimmunity.
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